Content includes:
- Identifying the often complex contributors to pain in persons with substance use disorders
- Selecting from diverse clinical strategies and implementing to provide safe and effective pain treatment
- Comfortably manage pharmacologic pain treatment in patients on opioids including buprenorphine/nx & other MATs
- Phenomenology of pain & substance use
- Principles of pain treatment in opioid & other substance use disorders
- Practical considerations in acute, chronic and terminal pain in patient on MAT
Presenter
Seddon Savage, MD
Dr. Savage is an associate professor on the adjunct faculty of Geisel School of Medicine at Dartmouth. She chairs the New Hampshire Opioid Task Force of the Governor’s Commission on Alcohol and Other Drugs and serves as an advisor to the Dartmouth Hitchcock Substance Use and Mental Health Initiative. Dr. Savage directed the Dartmouth Center on Addiction Recovery and Education (DCARE) from September 2004 through January 2016 and has held a number of national leadership positions in addiction medicine and pain medicine. She chaired the ASAM Committee on Pain from 1990-2003. She chaired the joint Liaison Committee on Pain and Addiction (LCPA) between the American Society of Addiction Medicine, the America Pain Society and the American Academy of Pain Medicine from 1999 through September 2005. She served as President of the American Pain Society in 2010-2012.
Learning Outcome(s)
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
Fisher JP et al. BMJ 1995;310:70 (untitled)
Pain in Men Wounded in Battle, Annals of Surgery, January 1946
Henry Knowles Beecher, Harvard Surgeon & Anesthesiologist
International Association for the Study of Pain. IASP Terminology. 2020; https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Pain. Accessed May 24, 2021.
Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med. 1994;331(2):69-73.
Leighton BL, Crock LW. Case Series of Successful Postoperative Pain Management in Buprenorphine Maintenance Therapy Patients. Anesth Analg. 2017;125(5):1779-1783.
Jonan AB, Kaye AD, Urman RD. Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures. Pain Physician. 2018;21(1):E1-e12.
Goel A, Azargive S, Weissman JS, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019;123(2):e333-e342.
Ward EN, Quaye AN, Wilens TE. Opioid Use Disorders: Perioperative Management of a Special Population. Anesth Analg. 2018;127(2):539-547.
Lembke A, Ottestad E, Schmiesing C. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period. Pain Med. 2019;20(3):425-428.
